bluebird bio (BLUE) Stock Price, News & Analysis

-0.05 (-5.14%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
8.16 million shs
Average Volume
8.83 million shs
Market Capitalization
$100.91 million
P/E Ratio
Dividend Yield
Price Target

bluebird bio MarketRank™ Stock Analysis

Analyst Rating
2.33 Rating Score
536.0% Upside
$5.87 Price Target
Short Interest
27.21% of Shares Sold Short
Dividend Strength
News Sentiment
0.07mentions of bluebird bio in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$4,134 Sold Last Quarter
Proj. Earnings Growth
From ($1.78) to ($1.72) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.78 out of 5 stars

Medical Sector

394th out of 907 stocks

Biological Products, Except Diagnostic Industry

59th out of 153 stocks

BLUE stock logo

About bluebird bio Stock (NASDAQ:BLUE)

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

BLUE Stock Price History

BLUE Stock News Headlines

Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
Bluebird bio Inc
Just Released: Insider's Secret to Trading Options
This Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.
Is Bluebird Bio Stock a Buy?
Better Buy: Bluebird Bio Vs. Novavax
See More Headlines
Receive BLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
12 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$3.60 million
Book Value
$2.37 per share


Free Float
Market Cap
$100.91 million
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Andrew ObenshainMr. Andrew Obenshain (Age 50)
    President, CEO & Director
    Comp: $1.04M
  • Mr. Thomas J. Klima (Age 52)
    Chief Commercial Officer & COO
    Comp: $654.97k
  • Mr. Richard A. Colvin M.D. (Age 58)
    Ph.D., Chief Medical Officer
    Comp: $696.24k
  • Mr. Christopher Krawtschuk CPA (Age 50)
    CFO, Principal Accounting Officer & Treasurer
  • Mr. Joseph D. Vittiglio Esq. (Age 52)
    J.D., Chief Legal & Business Officer and Secretary
  • Jess Rowlands
    Head of Corporate Communications
  • Ms. Andrea Walton
    Chief People Officer
  • Mr. Kasra Kasraian
    Senior Vice President of Technical Development & Operations
  • Mr. Scott Shoemaker
    Senior Vice President of Quality
  • Ms. Sarah Alspach
    Senior Vice President of External Affairs

BLUE Stock Analysis - Frequently Asked Questions

Should I buy or sell bluebird bio stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings
or view top-rated stocks.

What is bluebird bio's stock price target for 2024?

12 brokerages have issued 1-year price objectives for bluebird bio's shares. Their BLUE share price targets range from $1.02 to $13.00. On average, they anticipate the company's stock price to reach $5.87 in the next twelve months. This suggests a possible upside of 536.0% from the stock's current price.
View analysts price targets for BLUE
or view top-rated stocks among Wall Street analysts.

How have BLUE shares performed in 2024?

bluebird bio's stock was trading at $1.38 at the beginning of the year. Since then, BLUE stock has decreased by 33.1% and is now trading at $0.9229.
View the best growth stocks for 2024 here

Are investors shorting bluebird bio?

bluebird bio saw a drop in short interest in March. As of March 31st, there was short interest totaling 29,750,000 shares, a drop of 12.6% from the March 15th total of 34,040,000 shares. Based on an average daily volume of 9,070,000 shares, the days-to-cover ratio is presently 3.3 days.
View bluebird bio's Short Interest

When is bluebird bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our BLUE earnings forecast

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) announced its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.03. The biotechnology company had revenue of $12.40 million for the quarter, compared to the consensus estimate of $13.56 million. bluebird bio had a negative net margin of 419.64% and a negative trailing twelve-month return on equity of 34.32%. bluebird bio's revenue was up 17364.8% on a year-over-year basis. During the same quarter last year, the company posted ($0.92) EPS.

What ETFs hold bluebird bio's stock?

ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON) and Horizon Kinetics Medical ETF (MEDX).Global X Genomics & Biotechnology ETF (GNOM).

What is Nick Leschly's approval rating as bluebird bio's CEO?

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Nick Leschly has an approval rating of 74% among the company's employees.

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Enterprise Bank & Trust Co (0.03%). Insiders that own company stock include Andrew Obenshain, Anne-Virginie Eggimann, Christopher Krawtschuk, Jason Cole, Jessica Whitten, Nick Leschly, Richard A Colvin and Thomas J Klima.
View institutional ownership trends

How do I buy shares of bluebird bio?

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BLUE) was last updated on 4/25/2024 by Staff

From Our Partners